Numinus Wellness (TSE:NUMI) has released an update.
Numinus Wellness Inc. has issued clarifications on two previous news releases regarding their involvement in psychedelic-assisted therapy research and community network initiatives. The company reiterated its role in Cybin Inc.’s Phase 3 clinical trial, specifying that it holds no ownership interest in the CYB003 research and that results will be disclosed by Cybin at their discretion. Additionally, Numinus outlined the scope of its forthcoming Numinus Network community pilot, emphasizing that it will not include access to medical infrastructure for administering psychedelic substances within Canada’s regulatory framework.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.
